Editas Medicine Inc (EDIT)

NASDAQ
38.28
+0.26(+0.68%)
Pre Market
38.35
+0.07(+0.18%)
- Real-time Data
  • Volume:
    997,830
  • Bid/Ask:
    37.15/38.66
  • Day's Range:
    37.40 - 38.61

EDIT Overview

Prev. Close
38.02
Day's Range
37.4-38.61
Revenue
81.14M
Open
38.06
52 wk Range
27.12-99.95
EPS
-2.55
Volume
997,830
Market Cap
2.61B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,774,201
P/E Ratio
-
Beta
2.04
1-Year Change
13.73%
Shares Outstanding
68,153,255
Next Earnings Date
Nov 10, 2021
What is your sentiment on Editas Medicine Inc?
or
Market is currently closed. Voting is open during market hours.

Editas Medicine Inc News

Editas Medicine Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuySellNeutral
Technical IndicatorsStrong SellStrong BuyBuyStrong SellSell
SummarySellStrong BuyBuyStrong SellNeutral

Editas Medicine Inc Company Profile

Editas Medicine Inc Company Profile

Employees
235

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Read More
  • this company's stock price needs to start moving in the upward direction!
    0
    • the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.The Company will present a poster on its new method to drive high-level constitutive CD16 expression on the surface of iPSC-derived natural ***(iNK) cells through transgene knock-in (KI) at the GAPDH locus using an Editas-engineered AsCas12a. New preclinical data demonstrated that CD16 KI confers significantly increased cytotoxic activity in iNK cells against tumor cells compared with wild type iNK cells.
      0
      • this 37 dollar price point seems to me a very strong support.
        0
        • is it worthy to invest in this stock?
          0
          • No
            0
        • I don't get it. Fantastic results, and the shareprice drops like a rock!?
          0
          • well, now it is looking like a buy at 38 dollar. There is a very strong trendline there
            0
        • Today is the day.
          0
          • For what exacty !!!
            0
          • for positive research results on low and mid dose + a sell off xD
            0
        • ark invest sold 90,000 share of editas
          0
          • Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET. Editas Medicine, a leading genome editing company, announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration
            0
            • Results on september 29th , not september 10 th
              0
          • EDIT is the future
            0
            • Still holding, still loving it!  Don't plan on selling EVER.
              0
              • Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 2021 Virtual Healthcare Conference Fireside Chat (Virtual) Date: Friday, September 10, 2021 Time: 8:00 a.m. ET
                0
                • They will most likely report great news that day. I expect people to pop into this chat soon (too late again)
                  0
                • Let's hold a funny little stock price prediction: 140 dollar - 150 dollar ? by the time they announce
                  0
              • So glad I've been adding in. Got a lot in the 30's, a little bit more on the 40's, and a little bit more in the 50's above the 200 daily MA. Unfortunately, didn't pick any up in the 20's
                0
                • I like having 1k shares for these prices, but I didn't want to catch a falling knife with 100%, so I started with 500 around 38-ish, averaged down a bit, then averaged up. Average price 37.49
                  0
              • mashaallah
                0
                • Happy to see it doing well after earnings today!
                  0
                  • Lift off🚀
                    0
                    • Lost half from the peak
                      0
                      • stock is good long term
                        0
                        • Buy
                          0
                          • Yes
                            0
                        • buy
                          0
                          • Buy
                            0
                            • buy
                              1
                              • buy
                                1
                                • what happening with this stock... stay or leave?
                                  0
                                  • editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
                                    0
                                    • Dr Pay Whats the price point that you will buy? Monday will be the close for the offering at $66 which is $2 above what it is now, but there will be 3million more shares now. Will the market price increase because of that or will it continue down?
                                      0
                                    • Mister Bert Getting back into this company was my goal at any rate. being that is dropped down to 63.78, that was perfect for me. this stock will continue to climb up long term.
                                      1
                                    • Dr Pay Well its Monday and it hit that price again today a few times. Support is at $61 and it hit that at 8:05am today (but the entire market suspiciously dipped exactly at that point too). I dont know what to do with this. I wish the best of luck to you.
                                      0
                                  • editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.